Pharma and rare disease advocates press FDA at public hearing on Makary's National Priority Voucher pilot, urging formal rulemaking; 21 vouchers awarded so far.

The White House has used the program to reward companies that help its political goals.

On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National Priority Voucher (CNPV) pilot program, the flagship…